Literature DB >> 17041906

Protein- and mRNA-based phenotype-genotype correlations in DMD/BMD with point mutations and molecular basis for BMD with nonsense and frameshift mutations in the DMD gene.

Nathalie Deburgrave1, Fatma Daoud, Stéphane Llense, Jean Claude Barbot, Dominique Récan, Cécile Peccate, Arthur H M Burghes, Christophe Béroud, Luis Garcia, Jean-Claude Kaplan, Jamel Chelly, France Leturcq.   

Abstract

Straightforward detectable Duchenne muscular dystrophy (DMD) gene rearrangements, such as deletions or duplications involving an entire exon or more, are involved in about 70% of dystrophinopathies. In the remaining 30% a variety of point mutations or "small" mutations are suspected. Due to their diversity and to the large size and complexity of the DMD gene, these point mutations are difficult to detect. To overcome this diagnostic issue, we developed and optimized a routine muscle biopsy-based diagnostic strategy. The mutation detection rate is almost as high as 100% and mutations were identified in all patients for whom the diagnosis of DMD and Becker muscular dystrophy (BMD) was clinically suspected and further supported by the detection on Western blot of quantitative and/or qualitative dystrophin protein abnormalities. Here we report a total of 124 small mutations including 11 nonsense and frameshift mutations detected in BMD patients. In addition to a comprehensive assessment of muscular phenotypes that takes into account consequences of mutations on the expression of the dystrophin mRNA and protein, we provide and discuss genomic, mRNA, and protein data that pinpoint molecular mechanisms underlying BMD phenotypes associated with nonsense and frameshift mutations. (c) 2006 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17041906     DOI: 10.1002/humu.20422

Source DB:  PubMed          Journal:  Hum Mutat        ISSN: 1059-7794            Impact factor:   4.878


  47 in total

1.  One hundred twenty-one dystrophin point mutations detected from stored DNA samples by combinatorial denaturing high-performance liquid chromatography.

Authors:  Annalaura Torella; Amelia Trimarco; Francesca Del Vecchio Blanco; Anna Cuomo; Stefania Aurino; Giulio Piluso; Carlo Minetti; Luisa Politano; Vincenzo Nigro
Journal:  J Mol Diagn       Date:  2009-12-03       Impact factor: 5.568

2.  Identification of small molecule and genetic modulators of AON-induced dystrophin exon skipping by high-throughput screening.

Authors:  Debra A O'Leary; Orzala Sharif; Paul Anderson; Buu Tu; Genevieve Welch; Yingyao Zhou; Jeremy S Caldwell; Ingo H Engels; Achim Brinker
Journal:  PLoS One       Date:  2009-12-17       Impact factor: 3.240

3.  Reassessment of Genomic Sequence Variation to Harmonize Interpretation for Personalized Medicine.

Authors:  Kathryn B Garber; Lisa M Vincent; John J Alexander; Lora J H Bean; Sherri Bale; Madhuri Hegde
Journal:  Am J Hum Genet       Date:  2016-10-27       Impact factor: 11.025

4.  Whole dystrophin gene analysis by next-generation sequencing: a comprehensive genetic diagnosis of Duchenne and Becker muscular dystrophy.

Authors:  Yan Wang; Yao Yang; Jing Liu; Xiao-Chun Chen; Xin Liu; Chun-Zhi Wang; Xi-Yu He
Journal:  Mol Genet Genomics       Date:  2014-04-27       Impact factor: 3.291

Review 5.  Faulty RNA splicing: consequences and therapeutic opportunities in brain and muscle disorders.

Authors:  Vittoria Pagliarini; Piergiorgio La Rosa; Claudio Sette
Journal:  Hum Genet       Date:  2017-04-22       Impact factor: 4.132

6.  Somatic mosaicism due to a reversion variant causing hemi-atrophy: a novel variant of dystrophinopathy.

Authors:  Jaya Punetha; Simin Mansoor; Tulio E Bertorini; Akanchha Kesari; Kristy J Brown; Eric P Hoffman
Journal:  Eur J Hum Genet       Date:  2016-03-09       Impact factor: 4.246

7.  Clinical heterogeneity of duchenne muscular dystrophy (DMD): definition of sub-phenotypes and predictive criteria by long-term follow-up.

Authors:  Isabelle Desguerre; Christo Christov; Michele Mayer; Reinhard Zeller; Henri-Marc Becane; Sylvie Bastuji-Garin; France Leturcq; Catherine Chiron; Jamel Chelly; Romain K Gherardi
Journal:  PLoS One       Date:  2009-02-05       Impact factor: 3.240

8.  Exon exchange approach to repair Duchenne dystrophin transcripts.

Authors:  Stéphanie Lorain; Cécile Peccate; Maëva Le Hir; Luis Garcia
Journal:  PLoS One       Date:  2010-05-28       Impact factor: 3.240

9.  Microdystrophin ameliorates muscular dystrophy in the canine model of duchenne muscular dystrophy.

Authors:  Jin-Hong Shin; Xiufang Pan; Chady H Hakim; Hsiao T Yang; Yongping Yue; Keqing Zhang; Ronald L Terjung; Dongsheng Duan
Journal:  Mol Ther       Date:  2013-01-15       Impact factor: 11.454

10.  Somatic mosaicism for Duchenne dystrophy: evidence for genetic normalization mitigating muscle symptoms.

Authors:  Akanchha Kesari; Robert Neel; Lynne Wagoner; Brennan Harmon; Christopher Spurney; Eric P Hoffman
Journal:  Am J Med Genet A       Date:  2009-07       Impact factor: 2.802

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.